PolyPeptide Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

PolyPeptide Group (VTX:PPGN) Full Year 2023 Results

Key Financial Results

• Revenue: €320.4m (up 14% from FY 2022).
• Net loss: €51.4m (down from €7.77m profit in FY 2022).
• €1.56 loss per share (down from €0.23 profit in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

PolyPeptide Group Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 49%.

The primary driver behind last 12 months revenue was the Custom Projects segment contributing a total revenue of €154.5m (48% of total revenue). Notably, cost of sales worth €315.7m amounted to 99% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to €40.1m (71% of total expenses). Explore how PPGN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Life Sciences industry in Switzerland.

Performance of the Swiss Life Sciences industry.

The company's shares are up 44% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for PolyPeptide Group that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.